Dow Jones 9135.41 +38.72 10:30 am PST, July 22, 2003  NASDAQ 1702.78 +21.37 For info, visit access.smallcapnetwork.com S & P 500 985.94 +7.14 To be removed, please click here Russell 2000 461.09 +3.92 VOLUME 03: ISSUE 39  CEL-SCI joins exciting HIV/HPV initiative. Perhaps investors don't remember what can happen when the AIDS community gets behind a drug or therapy.  CEL-SCI (AMEX: CVM) announced today that they has become part of a group that will create The National HPV Co-Infection Alliance. Other partners include national AIDS organizations, advocacy groups, the HPV Foundation and pharma company Chronimed (NASDAQ: CHMD). The Alliance's mandate, described in the enclosed press release, is: "to educate the public about the growing HPV epidemic and to pursue the U.S. government for clinical research support.  Currently, the U.S. government is pursuing no clinical studies for the treatment of HIV/HPV co-infected women." Anyone familiar with AIDS treatment has heard of current therapies encompassing Protease Inhibitors as well as earlier AIDS drugs still on the market. If it were not for AIDS' community's activities and the R&D and subsequent availability of these AIDS therapies would not be anywhere near where they are today. That said, while over $8 billion is spent on AIDS research annually, nothing is spent on HIV/HPV co-infection. The Alliance's goal is to get significant dollars allocated for clinical trials.  Given Multikine's early trial results and potential efficacy, CEL-SCI stands to not only help drive awareness, but be on the cutting edge of new therapies targeted at co-infection. Multikine at the forefront This initiative should allow CEL-SCI to further research and develop its flagship drug, Multikine, which, according to CEO Geert Kersten, "is the only drug to have shown safety characteristics, as well as activity against both the cervical dysplasia and the HPV virus causing the dysplasia, in HIV/HPV co-infected women." HPV, or the Human Papilloma Virus, is responsible for the development of virtually all cases of cervical cancer. HIV infected women especially have shown a statistically relevant increased risk between that virus and this type of disease, which is second leading cause of cancer deaths. Condoms have shown little or no effect against HPV transmission. Education and treatment of this co-infection is the goal of the Alliance and by lobbying the government through the groups involved, as well as raising public awareness, it is hoped that new therapies will garner both funding and faster FDA approval. The official launch of the Alliance will take place in mid-September, 2003 at the US Conference on HIV/AIDS in New Orleans. The ultimate goal is to have HPV recognized as the major public health threat to people with AIDS at the World AIDS Conference in July 2004. Education is Power and potential treatment. Early Multikine data from CEL-SCI makes it an integral part of this initiative. CEO Kersten states; "most other drugs tested so far have failed due to toxicity in these co-infected women, and because we know of no other drug that attacks both the dysplasia and the virus simultaneously." The Alliance's creation an exciting and augers well for the treatment of HIV/HPV as well as for CEL-SCI. By raising awareness it will bring potentially effective drugs to the attention of those who hold the social policy and biotech R&D purse strings. The ability to combat this scourge which, as the most prevalent sexually transmitted disease in the world, can occur in up to 75 percent of sexually active women well deserves serious research and financial attention.  The Alliance intends to bring the disease from obscurity to a top priority.  Doing so can only be good for those afflicted with this potent virus, as well as for CEL-SCI's continuing effort to bring Multikine to market for this and a host of other viral applications.     PRESS  RELEASE VIENNA, Va., July 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) has joined with several AIDS organizations and advocacy groups, the HPV Foundation and Chronimed (NASDAQ:CHMD) to create the "The National HPV Co-infection Alliance."  The Alliance was created to address the growing epidemic of Human Papillomavirus (HPV) amongst patients infected with HIV (human immunodeficiency virus).  HPV is the world's leading sexually transmitted virus.  HPV is also a growing problem in HIV-infected women since their damaged immune system is unable to clear the HPV virus, which in turn leads to serious health complications, including cervical cancer.  Cervical cancer is the second leading cause of cancer deaths in women worldwide. HPV is also a growing problem in non-HIV infected patients.  It is estimated that more than 50% of college age women have been exposed to HPV. Gregory S. Henderson, MD, PhD, President of the HPV Foundation and author of the book "Women At Risk - The HPV Epidemic and Your Cervical Health", states that, "HPV infection is now known to be the cause of the majority of cancers of the female genitalia, including the cervix, vagina and vulva, and is thus a leading health problem in non-HIV-infected women.  Numerous studies show that up to 50% of college-aged women and men become infected with HPV.  A large concern among women who have HPV-induced cervical dysplasia (pre-cancerous growth potentially leading to cervical cancer) is that the treatment of this disease can require surgical procedures such as hysterectomy or procedures which can, in some cases, lead to cervical incompetence and the inability to bear children.  This incredibly common sexually transmitted disease can have devastating consequences, and yet the existence of this epidemic is essentially unknown to the " Tony Zappa, Pharm. D., MBA, and Executive Vice President of Operations of Chronimed, a leading distributor of HIV/HCV co-infection treatment, said, "Given the high co-infection rate between HIV and HPV, and the very limited knowledge of and around HPV within the general public and infected individuals, Chronimed is very interested in participating in this initiative to provide education and medication support." It is envisioned that the "National HPV Co-infection Alliance" will encompass municipal health authorities, pharmaceutical and biotechnology firms, AIDS service organizations (ASOs) and non-profit entities.  Its goal is to educate the public about the growing HPV epidemic and to pursue the U.S. government for clinical research support.  Currently, the U.S. government is pursuing no clinical studies for the treatment of HIV/HPV co-infected women. The initial campaign, dubbed, "Get Tested, Get Treated", will include a series of public service announcements (PSAs), treatment education symposiums directed at providers and patients, presentations at AIDS Education Treatment Centers (AETCs), an HIV Clinical Education Initiative (HCEI), and other similar programs throughout the U.S. "Our immunotherapy drug Multikine(R) is the only drug to have shown safety characteristics, as well as activity against both the cervical dysplasia and the HPV virus causing the dysplasia, in HIV/HPV co-infected women.  These findings should put Multikine at the forefront for testing of drugs geared to these co-infected women because most other drugs tested so far have failed due to toxicity in these co-infected women, and because we know of no other drug that attacks both the dysplasia and the virus simultaneously.  We are very pleased to see that other organizations are willing to join us in this fight for the search for an effective treatment for these women," said Geert Kersten, Chief Executive Officer, CEL-SCI Corporation. Human Papilloma Virus (HPV) is the most prevalent sexually transmitted infection in the world, occurring at some point in up to 75% of sexually active women (Groopman 1999).  Although HPV infection is widespread, most women are unaware that they are infected because they seldom have noticeable symptoms.  Almost all cervical cancers (99.7%) are directly linked to previous infection with one or more of the oncogenic (cancer-inducing) types of HPV (Judson 1992; Walboomers, et al 1999).  Unlike other STDs, barrier protection such as condoms, is not effective against HPV transmission.  There is substantial evidence that HIV-positive women are at increased risk of developing cervical cancer as well (Judson 1992).  In two studies, both from areas with high HIV prevalence, a statistically significant association between HIV and cervical cancer was reported. Rona Taylor, a member of the New York City Women's HIV Collaborative, stated that, "HPV expression persists longer in HIV-1 infected women with rising rates of infection for women of color. There are indications of a continued measurable rise in morbidity and mortality in HPV/HIV co-infection. Public awareness and education should be made a priority if efforts and advances are to be made in this arena." "Our milestone achievement will be to have HPV recognized at the 15th World AIDS Conference in July 2004 as the threat it truly is to the health of people with AIDS," said Jeannie Gibbs, the Northeast regional campaign director of the National HPV Co-infection Alliance, who also serves as a board member of the AIDS Action Council (www.aidsaction.org).  "We are actively recruiting regional directors across the country and planning to ensure that HIV/HPV co-infection gets the attention it so obviously deserves.  Federally sponsored clinical trials need to receive top priority". The official launch of the campaign "Get Tested, Get Treated" is scheduled to take place at a reception at the seventh annual United States Conference on HIV/AIDS (USCA), sponsored by the National Minority AIDS Council (NMAC), (www.nmac.org), on September 18-21, 2003 in New Orleans, Louisiana.  The USCA attracts over 3,000 service providers, people living with HIV/AIDS, policymakers, public officials, funders and other leaders each year, making it the largest U.S. AIDS-related gathering. CEL-SCI Corporation's drug, Multikine, a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, has been tested in over 190 cancer and HIV patients.  It has been shown to be safe, to reduce and/or eliminate tumors and to render the remaining cancer cells highly susceptible to follow-on radiation and chemotherapy. Chronimed, Inc. distributes pharmaceuticals and provides specialized patient management services nationwide for people with long-term chronic conditions, including HIV/AIDS, organ transplants and diseases treated with injectable medications.  StatScript Pharmacy is a nationwide network of community-based specialty pharmacies with 27 retail locations. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements.  Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected.  Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2002.  The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE  CEL-SCI Corporation   CO:  CEL-SCI Corporation; HPV Foundation; Chronimed; National Minority AIDS      Council; NMAC Got questions or comments? Send 'em here: editor@smallcapnetwork.com Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group, LLC has has been paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company for a period of one year. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.